Entries by CAPTIS

Catalent to buy cell and gene therapy CDMO MaSTherCell for $315m

Established in 2011, MaSTherCell Global is a technology-focused cell and gene therapy contract development and manufacturing organisation (CDMO) that serves cell therapy innovators. Catalent chair and CEO John The post Catalent to buy cell and gene therapy CDMO MaSTherCell for $315m appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb withdraws European application of Opdivo plus Yervoy for first-line treatment of advanced NSCLC

The application was originally filed in 2018 for patients with first-line NSCLC who have tumor mutational burden ≥10 mutations/megabase, based on the final analysis of progression-free survival, a The post Bristol-Myers Squibb withdraws European application of Opdivo plus Yervoy for first-line treatment of advanced NSCLC appeared first on Pharmaceutical Business review.

Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE

RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), The post Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE appeared first on Pharmaceutical Business review.

First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359

The dose-escalating study will enroll up to 12 individuals with metastatic, hormone receptor positive breast cancer with stable or minimally progressive disease, including bone metastasis. GMI-1359 is a The post First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359 appeared first on Pharmaceutical Business review.

Pulmatrix receives fast track designation for Pulmazole for the treatment of Asthma-ABPA

Pulmatrix is currently enrolling patients in its ongoing randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety, tolerability, pulmonary function and biomarker response of Pulmazole in subjects with The post Pulmatrix receives fast track designation for Pulmazole for the treatment of Asthma-ABPA appeared first on Pharmaceutical Business review.